UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan

Journal of Clinical Oncology

Volumn 25, Issue 18, 2007, Pages 2594-2600

  Stewart, Clinton F ^a   Panetta, John C ^a   O'Shaughnessy, Melinda A ^a   Throm, Stacy L ^a   Fraga, Charles H ^a   Owens, Thandranese ^a   Liu, Tiebin ^a   Billups, Catherine ^a   Rodriguez Galindo, Carlos ^a   Gajjar, Amar ^a   Furman, Wayne L ^a   McGregor, Lisa M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CEPHALOSPORIN; GEFITINIB; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; LOPERAMIDE;

ADOLESCENT; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHILD; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG ELIMINATION; FEMALE; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DNA, NEOPLASM; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 34447285021     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.2301     Document Type: Article

References (47)

1. Bomgaars L, Berg SL, Blaney SM: The development of camptothecin analogs in childhood cancers. Oncologist 6:506-516, 2001
2. Furman W, Stewart CF, Poquette C, et al: The direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999
3. Furman WL, Crews KR, Billups C, et al: Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 24:563-570, 2006
4. Bomgaars L, Kerr J, Berg S, et al: A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 46:50-55, 2006
5. Vassal G, Doz F, Frappaz D, et al: A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21:3844-3852, 2003
6. Houghton PJ, Cheshire PJ, Hallman JD, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403, 1995
7. Wagner LM, Crews KR, Iacono LC, et al: Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10:840-848, 2004
8. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194, 2001
9. Sparreboom A, de Jonge MJ, de Bruijn P, et al: Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747-2754, 1998
10. Ma MK, Zamboni WC, Radomski KM, et al: Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 6:813-819, 2000
11. Slatter JG, Schaaf LJ, Sams JP, et al: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following IV infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 28:423-433, 2000
12. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4192, 1991
13. Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854, 1998
14. Kiang TK, Ensom MH, Chang TK: UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132, 2005
15. Guillemette C: Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136-158, 2003
16. Skarke C, Grosch S, Geisslinger G, et al: Single-step identification of all length polymorphisms in the UGT1A1 gene promoter. Int J Clin Pharmacol Ther 42:133-138, 2004
17. Bosma PJ, Chowdhury JR, Bakker C, et al: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175, 1995
18. Bosma PJ, Seppen J, Goldhoorn B, et al: Bilirubin UDP- glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-17964, 1994
19. Schmid R: Gilbert's syndrome: A legitimate genetic anomaly? N Engl J Med 333:1217-1218, 1995
20. Bosma PJ, van der Meer IM, Bakker CT, et al: UGT1A1*28 allele and coronary heart disease: The Rotterdam Study. Clin Chem 49:1180-1181, 2003
21. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
22. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002
23. Ando Y, Ueoka H, Sugiyama T, et al: Polymorphisms of UDP- glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 24:111-116, 2002
24. Rouits E, Boisdron-Celle M, Dumont A, et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159, 2004
25. Marcuello E, Altes A, Menoyo A, et al: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682, 2004
26. Broniscer A, Iacono L, Chintagumpala M, et al: Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: Results of a multiinstitutional study (SJHG-98). Cancer 103:133-139, 2005
27. Crews KR, Stewart CF, Liu T, et al: Effect of Fractionated Ifosfamide on the Pharmacokinetics of Irinotecan in Pediatric Patients With Osteosarcoma. J Pediatr Hematol Oncol 26:764-767, 2004
28. Gajjar A, Chintagumpala MM, Bowers DC, et al: Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer 97:2374-2380, 2003
29. Owens TS, Dodds H, Fricke K, et al: High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 788:65-74, 2003
30. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. USC, Los Angeles, CA, Biomedical Simulations Resource, 1997
31. Steimer JL, Mallet A, Golmard JL, et al: Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed-effect model. Drug Metab Rev 15: 265-292, 1984
32. Nagar S, Blanchard RL: Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 38:393-409, 2006
33. Innocenti F, Ratain MJ: Irinogenetics and UGT1A: From genotypes to haplotypes. Clin Pharmacol Ther 75:495-500, 2004
34. McLeod HL, Watters JW: Irinotecan pharmacogenetics: Is it time to intervene? J Clin Oncol 22:1356-1359, 2004
35. Innocenti F, Vokes EE, Ratain MJ: Irinogenetics: What is the right star? J Clin Oncol 24:2221-2224, 2006
36. Ratain MJ: From bedside to bench to bedside to clinical practice: An odyssey with irinotecan. Clin Cancer Res 12:1658-1660, 2006
37. Paoluzzi L, Singh AS, Price DK, et al: Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44:854-860, 2004
38. Carlini LE, Meropol NJ, Bever J, et al: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226-1236, 2005
39. Goldberg RM, Sargent DJ, Morton RF, et al: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 24:3347-3353, 2006
40. Soepenberg O, Dumez H, Verweij J, et al: Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11:1504-1511, 2005
41. Soepenberg O, Dumez H, Verweij J, et al: Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol 23:889-898, 2005
42. Imamura H, Ikeda M, Furukawa H, et al: Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol 12:6522-6526, 2006
43. Drummond DC, Noble CO, Guo Z, et al: Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66:3271-3277, 2006
44. Takagi T, Saotome T: Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma 42:577-586, 2001
45. Blaney S, Berg SL, Pratt C, et al: A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 7:32-37, 2001
46. Bomgaars L, Kuttesch N, Bernstein M, et al: Correlation of UGT1A1 promoter genotype with pharmacokinetics and toxicity in pediatric patients receiving irinotecan (CPT-11). Proc Am Soc Clin Oncol 22:138, 2003
47. O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534-4538, 2006